Liver cancer starts in the liver. The risk factors for liver cancer include hepatitis, cirrhosis, or scarring of liver, being male and having low weight at birth. Symptoms include a lump or pain on the right side of the abdomen and yellowing of the skin. Treatment of liver cancer may include chemotherapy, radiation and surgery.
Pharmaceutical and Healthcare latest pipeline guide Liver Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Liver Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Liver Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Liver Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 17, 76, 52, 8, 121 and 19 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 15, 8, 1, 30 and 3 molecules, respectively.
Liver Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cancer (Oncology).
– The pipeline guide reviews pipeline therapeutics for Liver Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Liver Cancer (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Liver Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Liver Cancer (Oncology)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Liver Cancer (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Liver Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Liver Cancer Overview 11
Therapeutics Development 12
Liver Cancer – Therapeutics under Development by Companies 14
Liver Cancer – Therapeutics under Investigation by Universities/Institutes 29
Liver Cancer – Pipeline Products Glance 32
Liver Cancer – Products under Development by Companies 35
Liver Cancer – Products under Investigation by Universities/Institutes 56
Liver Cancer – Companies Involved in Therapeutics Development 60
Liver Cancer – Therapeutics Assessment 245
Drug Profiles 277
Liver Cancer – Dormant Projects 1096
Liver Cancer – Discontinued Products 1116
Liver Cancer – Product Development Milestones 1120
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get in touch: